Re: Comparison of immediate vs. deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial

Detalles Bibliográficos
Autores principales: Minervini, Andrea, Mari, Andrea, Di Maida, Fabrizio, Campi, Riccardo, Carini, Marco, Lapini, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2019
Materias:
Editorial Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797348/
https://www.ncbi.nlm.nih.gov/pubmed/35117099
http://dx.doi.org/10.21037/tcr.2019.03.08
_version_ 1784641529022775296
author Minervini, Andrea
Mari, Andrea
Di Maida, Fabrizio
Campi, Riccardo
Carini, Marco
Lapini, Alberto
author_facet Minervini, Andrea
Mari, Andrea
Di Maida, Fabrizio
Campi, Riccardo
Carini, Marco
Lapini, Alberto
author_sort Minervini, Andrea
collection PubMed
description
format Online
Article
Text
id pubmed-8797348
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-87973482022-02-02 Re: Comparison of immediate vs. deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial Minervini, Andrea Mari, Andrea Di Maida, Fabrizio Campi, Riccardo Carini, Marco Lapini, Alberto Transl Cancer Res Editorial Commentary AME Publishing Company 2019-03 /pmc/articles/PMC8797348/ /pubmed/35117099 http://dx.doi.org/10.21037/tcr.2019.03.08 Text en 2019 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
spellingShingle Editorial Commentary
Minervini, Andrea
Mari, Andrea
Di Maida, Fabrizio
Campi, Riccardo
Carini, Marco
Lapini, Alberto
Re: Comparison of immediate vs. deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial
title Re: Comparison of immediate vs. deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial
title_full Re: Comparison of immediate vs. deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial
title_fullStr Re: Comparison of immediate vs. deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial
title_full_unstemmed Re: Comparison of immediate vs. deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial
title_short Re: Comparison of immediate vs. deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial
title_sort re: comparison of immediate vs. deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the surtime randomized clinical trial
topic Editorial Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797348/
https://www.ncbi.nlm.nih.gov/pubmed/35117099
http://dx.doi.org/10.21037/tcr.2019.03.08
work_keys_str_mv AT minerviniandrea recomparisonofimmediatevsdeferredcytoreductivenephrectomyinpatientswithsynchronousmetastaticrenalcellcarcinomareceivingsunitinibthesurtimerandomizedclinicaltrial
AT mariandrea recomparisonofimmediatevsdeferredcytoreductivenephrectomyinpatientswithsynchronousmetastaticrenalcellcarcinomareceivingsunitinibthesurtimerandomizedclinicaltrial
AT dimaidafabrizio recomparisonofimmediatevsdeferredcytoreductivenephrectomyinpatientswithsynchronousmetastaticrenalcellcarcinomareceivingsunitinibthesurtimerandomizedclinicaltrial
AT campiriccardo recomparisonofimmediatevsdeferredcytoreductivenephrectomyinpatientswithsynchronousmetastaticrenalcellcarcinomareceivingsunitinibthesurtimerandomizedclinicaltrial
AT carinimarco recomparisonofimmediatevsdeferredcytoreductivenephrectomyinpatientswithsynchronousmetastaticrenalcellcarcinomareceivingsunitinibthesurtimerandomizedclinicaltrial
AT lapinialberto recomparisonofimmediatevsdeferredcytoreductivenephrectomyinpatientswithsynchronousmetastaticrenalcellcarcinomareceivingsunitinibthesurtimerandomizedclinicaltrial

Ejemplares similares